Business Context and Reporting Period
This Form 8-K was filed by Palatin Technologies, Inc. on August 14, 2025. The report details a material definitive agreement entered into with Boehringer Ingelheim International GmbH (BI) regarding the development of melanocortin receptor-targeted peptides for retinal diseases. The filing also addresses the Company's recent delisting from the NYSE American due to low stock price and subsequent trading on OTC markets.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, cash flow, or debt metrics. Financial data is limited to the terms of the new collaboration agreement:
- Upfront Payment: €2.0 million (approximately $2.3 million USD).
- Near-Term Research Milestones: Up to €18.0 million (approximately $20.9 million USD).
- Success-Based Milestones: Up to €260 million (approximately $301.6 million USD) for development, regulatory, and commercial achievements.
- Royalties: Tiered royalties on net commercial sales, subject to reductions for patent expiration and generic competition.
- Research Period: Two-year collaborative research period at BI's expense, extendable by up to six months.
Material Changes and Corporate Status
The Company has undergone significant changes in its listing status:
- Delisting: NYSE American determined the Company was no longer suitable for listing due to low selling price. Trading was suspended on May 7, 2025.
- OTC Trading History:
- May 8, 2025 – June 6, 2025: Traded on the Pink Market (Symbol: PTNT).
- June 9, 2025 – August 11, 2025: Traded on the OTCQB Market (Symbol: PTNT).
- August 12, 2025 – Present: Traded on the OTCQB Market (Symbol: PTNTD).
- Intellectual Property: Palatin assigned certain patent rights to BI under the new agreement.
Outlook, Risks, and Management Commentary
Management highlights the strategic partnership with BI to commercialize first-in-class peptides for diabetic retinopathy. The agreement includes forward-looking statements regarding the potential for milestone payments and royalties, which are not guaranteed.
Risks and Contingencies:
- Termination Rights: BI may terminate the agreement for any reason after a specified notice period. Either party may terminate for bankruptcy or material, uncured breach.
- Market Status: The Company is no longer listed on a national exchange, which may impact liquidity and investor perception.
- Forward-Looking Disclaimers: Actual results may differ materially from expectations due to various risks and uncertainties. The Company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the exact terms of the royalty reductions and the definition of "net commercial sales" in the full agreement text (to be filed in the 10-Q for the quarter ending September 30, 2025).
- Confirm the current trading volume and liquidity of the stock under the new symbol "PTNTD" on the OTCQB Market.
- Review the specific patents assigned to BI to assess the remaining intellectual property portfolio of Palatin.
- Monitor the Company's cash position to determine if the €2.0 million upfront payment is sufficient to fund operations until the first research milestone is achieved.